Brief: Knight Therapeutics To Acquire Grupo Biotoscana

Knight Therapeutics

21/10/2019 12:13

Oct 21 (Reuters) - Knight Therapeutics Inc  GUD.TO :
    * KNIGHT THERAPEUTICS TO ACQUIRE GRUPO BIOTOSCANA,
ESTABLISHING A
LATIN AMERICAN GROWTH PLATFORM
    * KNIGHT THERAPEUTICS INC - DEAL FOR BRL 10.96 PER SHARE
    * KNIGHT THERAPEUTICS INC - WILL PAY APPROXIMATELY BRL 596
MILLION
OR C$189 MILLION IN CASH CONSIDERATION FOR 51.21% CONTROLLING
INTEREST IN GBT.
    * KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF TRANSACTION,
KNIGHT WILL LAUNCH A MANDATORY TENDER OFFER TO ACQUIRE REMAINING
48.79% INTEREST IN GBT
    * KNIGHT THERAPEUTICS INC - EXPECTED CASH CONSIDERATION IS
OF
APPROXIMATELY BRL 568 MILLION OR C$180 MILLION FOR REMAINING
48.79% INTEREST IN GBT
    * KNIGHT THERAPEUTICS - WILL ACQUIRE INTEREST IN BIOTOSCANA
INVESTMENTS FROM GROUP THAT INCLUDES ADVENT INTERNATIONAL &
ESSEX WOODLANDS, AMONG OTHERS
    * KNIGHT THERAPEUTICS INC - PRIVATE TRANSACTION WILL BE
FULLY
FUNDED FROM CASH ON KNIGHT'S BALANCE SHEET
    * KNIGHT THERAPEUTICS INC - WILL BECOME CONTROLLING
SHAREHOLDER
AND WILL APPOINT ITS REPRESENTATIVES TO BOARD OF GBT
    * KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF ACQUISITION
OF
100% OF GBT, CO EXPECTS TO PAY AGGREGATE EQUITY PURCHASE PRICE
OF BRL 1,164 MILLION/C$369 MILLION
    * KNIGHT THERAPEUTICS - FOLLOWING COMPLETION OF ACQUISITION
OF
100% OF GBT, KNIGHT EXPECTS TO PAY ENTERPRISE VALUE OF BRL 1,318
MILLION OR C$418 MILLION

Source text for Eikon:  ID:nGNX3LGdnV 
Further company coverage:  GUD.TO 

 ((Reuters.Briefs@thomsonreuters.com;))